The manufacturer of the nucleoside analogue reverse transcriptase inhibitor, didanosine (Videx®), has advised health care providers of a change in prescribing information. The results of a recent clinical trial have demonstrated that the treatment response rate of once-daily didanosine was significantly lower than in the comparator arm. Although once daily dosing is available, it should only be considered for adult patients whose management requires this administration.

It is therefore recommended that the more effective dosing frequency of didanosine is twice-daily.

Reference: Letter from Bristol-Myers Squibb Company, USA, dated 1 August 2000.